Your browser doesn't support javascript.
loading
Development of Hormonal Intravaginal Rings: Technology and Challenges.
Rafiei, Fojan; Tabesh, Hadi; Farzad, Shayan; Farzaneh, Farah; Rezaei, Maryam; Hosseinzade, Fateme; Mottaghy, Khosrow.
Afiliação
  • Rafiei F; Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.
  • Tabesh H; Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.
  • Farzad S; Department of Biomedical Engineering, University of Southern California, Los Angeles, California, United States.
  • Farzaneh F; Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Rezaei M; Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.
  • Hosseinzade F; Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.
  • Mottaghy K; Institute of Physiology, RWTH Aachen University, Aachen, Germany.
Geburtshilfe Frauenheilkd ; 81(7): 789-806, 2021 Jul.
Article em En | MEDLINE | ID: mdl-34276064
Intravaginal rings (IVRs) are minimally invasive polymeric devices specifically designed to be used for the sustained and prolonged release of various type of drugs such as hormones. One of the benefits of using topical drug delivery systems (e.g., IVRs) is the fact that systemic drug delivery may cause drug resistance due to elevated drug levels. Topical drug delivery also provides higher concentrations of the drug to the target site and has fewer side effects. In addition, when a drug is administered vaginally, the hepatic first-pass effect is avoided, resulting in higher absorption. Contraception and treatments for specific diseases such as endometriosis and hormone deficiencies can be improved by the administration of hormones via an IVR. This article aims to classify and compare various designs of commercially available and non-commercial hormonal IVRs and to analyze their performance. Current challenges affecting the development of IVRs are investigated, and proposed solutions are discussed. A comprehensive search of publications in MEDLINE/PubMed and of commercial product data of IVRs was performed, and the materials, designs, performance, and applications (e.g., contraception, endometriosis, estrogen deficiency and urogenital atrophy) of hormonal IVRs were thoroughly evaluated. Most hormonal IVRs administer female sex hormones, i.e., estrogen and progestogens. In terms of material, IVRs are divided into 3 main groups: silicone, polyurethane, and polyethylene-co-vinyl acetate IVRs. As regards their design, there are 4 major designs for IVRs which strongly affect their performance and the timing and rate of hormone release. Important challenges include reducing the burst release and maintaining the bioavailability of hormones at their site of action over a prolonged period of administration as well as lowering production costs. Hormonal IVRs are a promising method which could be used to facilitate combination therapies by administering multiple drugs in a single IVR while eliminating the side effects of conventional drug administration methods. IVRs could considerably improve women's quality of life all over the world within a short period of time.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Geburtshilfe Frauenheilkd Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Geburtshilfe Frauenheilkd Ano de publicação: 2021 Tipo de documento: Article